Does blockade of the monocyte chemoattractant protein-1 receptor pathway ameliorate myocardial injury in animal models of ischemia and reperfusion?
These findings demonstrate a pathogenic role for MCP-1 in animal models of I/R and support the consideration of MCP-1 as a therapeutic target in myocardial ischemia.
Our findings indicate that low miR-34c level is a novel promising biomarker in predicting prognosis in patients with de novo AML.